ANDA 90354, held by Antibiotice. Ampicillin Sodium.
As of Nov 21, 2026, ANDA 90354 (Ampicillin Sodium), held by Antibiotice, was first approved by FDA on Dec 28, 2009, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by S treptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 28, 2009 | Original application | Approved | None posted |
| Ampicillin SodiumEQ 250MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| Ampicillin SodiumEQ 500MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| Ampicillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| Ampicillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| May 1, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 23, 2018 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 23, 2018 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 28, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters